Matt Dellatorre

could you comment on whether priority review is still a possibility there

could you share your latest expectations in terms of the label, in particular, how you expect opioid sparing to be reflected there

could you comment on any feedback thus far from the FDA regarding the potential for an opioid-sparing label

should we think about '26 looking more like '25, where it is more kind of capital return? Or directionally, does '26 look more like that 50-50 balance

how much of a priority is growth at this point? And what level of growth are you now aiming for as we think about full year '26 and beyond